Kamada (NASDAQ:KMDA) Downgraded by StockNews.com

StockNews.com lowered shares of Kamada (NASDAQ:KMDA) from a strong-buy rating to a buy rating in a report released on Tuesday morning.

Several other analysts also recently commented on the stock. HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Kamada in a report on Thursday, August 15th. Stifel Nicolaus assumed coverage on shares of Kamada in a research note on Wednesday, July 3rd. They issued a buy rating and a $18.00 price objective for the company.

Kamada Stock Up 1.4 %

Shares of NASDAQ:KMDA opened at $5.80 on Tuesday. The business’s 50 day moving average is $5.54 and its 200 day moving average is $5.55. Kamada has a 12-month low of $4.08 and a 12-month high of $6.53. The stock has a market cap of $333.38 million, a price-to-earnings ratio of 25.22 and a beta of 1.06.

Institutional Investors Weigh In On Kamada

A number of hedge funds have recently made changes to their positions in the business. Y.D. More Investments Ltd increased its holdings in Kamada by 1,956.0% during the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock worth $3,643,000 after buying an additional 690,842 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Calton & Associates Inc. bought a new stake in shares of Kamada in the 4th quarter worth approximately $111,000. Finally, Aristides Capital LLC lifted its stake in Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after purchasing an additional 16,635 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.